Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein.

OBJECTIVE The long-term effects of surgical fibroblast growth factor 2 therapy are examined. METHODS In a randomized, double-blind study, fibroblast growth factor 2 (10 microg or 100 microg) or placebo (n = 8 each) was delivered in the ungraftable myocardial territory of patients concomitantly undergoing coronary artery bypass grafting. Patients were followed up to 32.2 +/- 6.8 months postoperatively with clinical assessment and nuclear perfusion imaging. RESULTS Baseline patient characteristics were similar between the 3 groups. There were 2 late deaths, one of pancreatic cancer and one of undetermined cause (both in the 100-microg fibroblast growth factor 2 group). Two patients (both in the control group) underwent a total of 6 repeat cardiac catheterizations for recurrent coronary events. Mean Canadian Cardiovascular Society angina class improved at late follow-up from baseline in all groups (P < or = .02); however, patients treated with either dose of fibroblast growth factor 2 had significantly more freedom from angina recurrence than those treated with placebo (P =.03). Late nuclear perfusion scans revealed a persistent reversible or a new, fixed perfusion defect in the ungraftable territory of 4 of 5 patients who received placebo versus only 1 of 9 patients treated with fibroblast growth factor 2 (P =.02). The overall sum of left ventricular stress perfusion defect scores was also lower in fibroblast growth factor 2-treated patients than in control subjects (1.3 +/- 1.4 vs 3.9 +/- 2.1, respectively; P =.04). A trend toward a higher late left ventricular ejection fraction was noted in fibroblast growth factor 2-treated patients (55.1% +/- 14.6% vs 44.3% +/- 6.5%, fibroblast growth factor 2-treated patients versus control subjects; P =.12). CONCLUSIONS These data suggest that surgical angiogenic therapy with sustained-release fibroblast growth factor 2 may result in a prolonged myocardial revascularization effect that could translate into clinical benefit.

[1]  T. Henry,et al.  Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2: Double-Blind, Randomized, Controlled Clinical Trial , 2002, Circulation.

[2]  F. Sellke,et al.  Therapeutic angiogenesis in cardiology using protein formulations. , 2001, Cardiovascular research.

[3]  R O Bonow,et al.  Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. , 2000, Circulation.

[4]  Henry Td,et al.  Review of Preclinical and Clinical Results with Vascular Endothelial Growth Factors for Therapeutic Angiogenesis. , 2000 .

[5]  B. Schumacher,et al.  Angiogenesis in ischemic human myocardium: clinical results after 3 years. , 2000, The Annals of thoracic surgery.

[6]  M. Leinonen,et al.  Infections, inflammation, and the risk of coronary heart disease. , 2000, Circulation.

[7]  J. Pearlman,et al.  Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. , 1999, Circulation.

[8]  M. Post,et al.  Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. , 1999, Circulation.

[9]  F. Sellke,et al.  Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[10]  J D Pearlman,et al.  Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. , 1998, The Annals of thoracic surgery.

[11]  B. V. von Specht,et al.  Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. , 1998, Circulation.

[12]  H. Dvorak,et al.  Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. , 1996, The American journal of pathology.

[13]  P. Libby,et al.  Cytokines Regulate Vascular Functions Related to Stability of the Atherosclerotic Plaque , 1995, Journal of cardiovascular pharmacology.

[14]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[15]  Joan W. Miller,et al.  Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. , 1994, American journal of ophthalmology.

[16]  S M Schwartz,et al.  Angiogenesis in human coronary atherosclerotic plaques. , 1994, The American journal of pathology.

[17]  W Grossman,et al.  Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. , 1994, The Journal of clinical investigation.

[18]  E. Edelman,et al.  Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R Langer,et al.  Controlled and modulated release of basic fibroblast growth factor. , 1991, Biomaterials.